TAKEDA - Multiple Challenges Blur Future!

https://marketpublishers.com/r/TA48CA627FAEN.html

Date: August 2011
Pages: 8
Price: US$ 140.00 (Single User License)
ID: TA48CA627FAEN

Abstracts

There are three major concerns for Takeda – 1) Takeda has got European exposure by the Nycomed acquisition, but as both companies are in different segments, cost synergy will be minimal and therefore does not justify the heavy acquisition price of $13.5b. Nycomed total revenue will not be sufficient to negate revenue loss from Actos in FY 12. Moreover, no revenue addition from the Nycomed pipeline is expected. 2) Safety related issues with Actos affects market prospects of Takeda's key candidate Aloglipin's combination drug with Actos and, 3) Pipeline is full of late stage good high-risk-high-return candidates like TAK 700, LUAA21004, MLN002 and TAK 875, but no major near-term milestone expected – overall, we do not see any improvement in Takeda's business in next 2-3 years.

Contents

COMPANIES MENTIONED

TAKEDA, 4502

I would like to order

Product name: TAKEDA - Multiple Challenges Blur Future!

Product link: https://marketpublishers.com/r/TA48CA627FAEN.html

Price: US$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/TA48CA627FAEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970